Stop Hep B @ Birth
Stop Hep B @ Birth: Community-Oriented Care Model for the Prevention of Mother-To-Child Transmission of Hepatitis B in Peri-Urban Yangon
調査の概要
状態
条件
詳細な説明
An estimated 248 million people worldwide are chronically infected with hepatitis B virus (HBV); and 75% of them live in Asia. Mother-to-child transmission (MTCT) accounts for the majority of chronic hepatitis B infections in Southeast Asia. Elimination of MTCT of HBV is theoretically possible with a comprehensive suite of interventions that includes birth dose vaccination, hepatitis B immune globulin, and antenatal antiviral therapy (e.g., tenofovir). However, the ideal gestational age to initiate antenatal tenofovir remains undefined; and evidence is lacking for implementation strategies capable of providing cost-effective, equitable access to a comprehensive suite of interventions to prevent MTCT of HBV in low-resource settings.
Component I: Prevention of Vertical Transmission Pregnant women living in the study area will be identified and screened for hepatitis B by a network of antenatal care (ANC) providers and existing community outreach workers; HBsAg positive patients will be invited to participate in the study. Consenting participants will provide serum samples to assess eligibility for anti-viral therapy: creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, HCV, HIV. Pregnant women eligible for antiviral therapy according to WHO criteria, or who have viral load (VL) >200,000 IU/mL, will be treated with tenofovir starting at 20 weeks gestation through 4 weeks postpartum. Hospital-based delivery will be encouraged. All newborns, including those delivered at home, will receive the HBV birth dose vaccine within 24 hours of delivery, and newborns of women on tenofovir treatment will also receive Hepatitis B Immunoglobulin within 24 hours after delivery. Children will be linked to routine immunization services in Myanmar to complete their HBV vaccination series (HBV is co-formulated in a pentavalent vaccine). Maternal VL will be measured at delivery; infants will be tested for hepatitis B infection at 24-28 weeks postpartum.
Component II -- Household Screening and Treatment The household members of HBsAg positive pregnant women who consent to participate in the study will be screened for HBV-related immune status and chronic HBV infection. Non-immune individuals (HBsAb/Ag negative) will be vaccinated; HBsAg positive household members will be assessed for treatment eligibility and initiated on anti-viral therapy according to World Helath Organization guidelines. Eligible household members will also be screened every six months for hepatocellular carcinoma (HCC) by liver ulatrasound and alpha-fetoprotein levels
Qualitative Study:
In-depth interviews with approximately 30 HBsAg-positive women, 30 HBVsAg-negative women, and 20 household members of study participants will be conducted to assess barriers and facilitators related to HBV testing and treatment. Approximately 15 key-informant interviews with healthcare providers and community leaders will also be conducted. Sample size will depend on data saturation and will be adjusted based on results of data analysis during the study.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Khin Pyone Kyi, MD
- 電話番号:+95 9 250 022 398
- メール:pmcthbv2018kpk@gmail.com
研究連絡先のバックアップ
- 名前:Eindra Htoo, MD
- 電話番号:+95 9 975 477 478
- メール:eindrahtoo@cpintl.org
研究場所
-
-
-
Yangon、ミャンマー
- 募集
- BK Kee Clinic
-
コンタクト:
- Hnin Nandar Htut
- メール:nandar@bkkeefoundation.org
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Pregnant women >= 18 years of age
- Gestational age =<34 weeks
- Test positive for HBsAg
- Live in study site area in South Dagon and Dagon Seikkan Townships, Yangon Region
- Give informed consent to participate in the study
- Newborns and household members of pregnant women enrolled in the study according to previous inclusion criteria
Exclusion Criteria:
- Alanine aminotransferase (ALT) levels >300 IU/L
For qualitative study:
Inclusion criteria
- Key informants (e.g., healthcare providers and community leaders in the study area) OR
- HBsAg+ women and their household members in the study area
- HBsAg- women and their household members in the stud area
- Give informed consent to participate in the study
- History of renal dysfunction
- CrCL < 50mL/min
- ALT>5 times the upper limit of normal (ULN)
- Evidence of decompensated cirrhosis (e.g., jaundice, ascites, history of upper gastrointestinal bleeding/esophageal varices, and hepatic encephalopathy)
- Any concomitant condition or treatment that, in view of the clinical site investigator, would contraindicate participation or satisfactory follow-up in the study HIV positive status unless 1) they are currently on additional ART therapy, or 2) their viral load is demonstrated to be <50 copies. Women who are newly diagnosed with HIV and referred to start a TDF-based regimen may be considered eligible once they have started the TDF-based regimen.
- Concurrent participation in any other clinical trial without written agreement of the study team
- Does not intend to deliver within catchment area, and/or intends to migrate before newborn follow-up is complete
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Tenofovir Disoproxil Fumerate
Pregnant women (>=20 weeks of gestation) will be treated with TDF if clinically eligible; newborns will receive birth dose vaccine (and HBIG if eligible).
Non-eligible women will be treated according to normal practices; newborns will still receive birth dose vaccine.
|
Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
他の名前:
Treated according to normal Myanmar processes for HBV positive patients
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Vaccine within 24 hours
時間枠:Within 24 hours of birth
|
Proportion of newborns of HBsAg positive mothers receiving HBV vaccine within 24 hours of birth
|
Within 24 hours of birth
|
Effective treatment of pregnant women
時間枠:During pregnancy (until delivery) of each woman, average of 9 months
|
Proportions of pregnant women with chronic HBV (HBsAg positive) who are (a) linked to care (attend BK Kee Clinic for assessment of treatment eligibility); (b) complete TDF eligibility testing; (c) initiate tenofovir treatment (TDF, among those eligible); (d) adhere to TDF treatment until delivery and (e) continue treatment until 4 weeks post-partum o Low/medium/high high medication adherence are defined, respectively, as ≤6, 6-7 or 8 points on the Morisky Medication Adherence Scale (MMAS-8) |
During pregnancy (until delivery) of each woman, average of 9 months
|
Household contact screening
時間枠:Upon identification of participating women, until the end of the project, average of 1 year
|
Proportions of adult household contacts who (a) are screened for chronic HBV infection and immunity (HBsAg/Ab); (b) are linked to care (among HBsAg positive) or vaccinated (if HBsAb negative); (c) complete appropriate testing for hepatocellular carcinoma (HCC) screening, (d) eligible for TDF treatment; (e) initiate chronic HBV treatment with TDF
|
Upon identification of participating women, until the end of the project, average of 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Total screening of mothers
時間枠:During pregnancy (until delivery) of each woman, average of 9 months
|
Proportion of pregnant women in the target population who are:
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Antenatal care for HBV positive pregnant mothers
時間枠:During pregnancy (until delivery) of each woman, average of 9 months
|
Proportions of pregnant women with chronic HBV who:
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Vaccination of HBV negative pregnant mothers
時間枠:During pregnancy (until delivery) of each woman, average of 9 months
|
Proportion of women who tested negative for HBsAg and HBsAb at baseline who complete the HBV vaccination schedule
|
During pregnancy (until delivery) of each woman, average of 9 months
|
Treatment of high viral load pregnant mothers
時間枠:At delivery; during antenatal care testing; at 4 months postpartum, throughout the project, average of 12 months
|
Among women who had VL>200,000 IU/mL at baseline and were eligible for TDF treatment:
|
At delivery; during antenatal care testing; at 4 months postpartum, throughout the project, average of 12 months
|
Viral suppression
時間枠:At delivery, throughout the project (one off)
|
Associations of maternal viral suppression (VL <200,000 at delivery and: baseline HBV VL, duration of exposure to TDF, and TDF adherence
|
At delivery, throughout the project (one off)
|
Mother-to-child transmission
時間枠:At 28 weeks postpartum, throughout the project (one off)
|
Proportion of infants born to HBsAg positive mothers who
|
At 28 weeks postpartum, throughout the project (one off)
|
Household screening
時間枠:At household screening, throughout the project (one off)
|
Among household members screened for HBsAg and HBsAb: o Prevalence of chronic infection (% HBsAg positive); and immune status (% HBsAb positive and HBsAg negative) |
At household screening, throughout the project (one off)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Completed vaccination courses
時間枠:Before age 1, average of 1 year
|
Proportion of infants of HBsAg positive mothers who complete HBV vaccination prior to study termination, before and after coronavirus- and coup- related delays in public vaccination program
|
Before age 1, average of 1 year
|
Proportion of pregnant women with HBsAg identified by surveillance team members
時間枠:During pregnancy, average of 9 months
|
Proportion of pregnant women with HBsAg identified by surveillance team members
|
During pregnancy, average of 9 months
|
Timeliness of pregnancy surveillance
時間枠:During pregnancy, average of 9 months
|
Among pregnant women identified by surveillance team members:
|
During pregnancy, average of 9 months
|
Equity of intervention
時間枠:During pregnancy and in first year after delivery, average of 16 months
|
Distributions of select outcomes according to age, sex and axes of social disadvantage: household wealth; educational attainment; occupation; and ethnic/religious affiliation
|
During pregnancy and in first year after delivery, average of 16 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Khin Phone Kyi, MD、Myanmar Liver Foundation
- 主任研究者:Adam K Richards, MD、University of California, Los Angeles
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HBV2020
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
B型肝炎の臨床試験
-
Lapo Alinari募集MYC、BCL2、および BCL6 再構成を伴う再発高悪性度 B 細胞性リンパ腫 | MYC、BCL2、および BCL6 再構成を伴う難治性高悪性度 B 細胞性リンパ腫 | MYCおよびBCL2またはBCL6再構成を伴う再発性高悪性度B細胞リンパ腫 | MYCおよびBCL2またはBCL6再構成を伴う難治性高悪性度B細胞リンパ腫 | 再発性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | 難治性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | びまん性大細胞型B細胞リンパ腫への形質転換型無痛性B細胞非ホジキンリンパ腫 | 再発性びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型 | 難治性びまん性大細胞型...アメリカ
-
Curocell Inc.募集高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫(DLBCL) | 原発性縦隔大細胞型B細胞リンパ腫(PMBCL) | 形質転換濾胞性リンパ腫(TFL) | 難治性大細胞型B細胞リンパ腫 | 再発大細胞型B細胞リンパ腫大韓民国
-
University of NebraskaBristol-Myers Squibb募集濾胞性リンパ腫 | 難治性非ホジキンリンパ腫 | 高悪性度B細胞リンパ腫 | DLBCL - びまん性大細胞型 B 細胞性リンパ腫 | 非ホジキンリンパ腫の再発 | 縦隔大細胞型B細胞リンパ腫 | 無痛性B細胞非ホジキンリンパ腫アメリカ
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.わからない
-
Nathan DenlingerBristol-Myers Squibb募集B細胞非ホジキンリンパ腫再発性 | びまん性大細胞型 B 細胞リンパ腫 - 再発性 | 濾胞性リンパ腫-再発性 | 高悪性度B細胞リンパ腫再発性 | 原発性縦隔大細胞型 B 細胞リンパ腫 - 再発性 | 緩徐進行性B細胞非ホジキンリンパ腫からびまん性大細胞型B細胞リンパ腫への転移 - 再発性 | B細胞非ホジキンリンパ腫難治性 | 難治性びまん性大細胞型 B 細胞リンパ腫 | 濾胞性リンパ腫難治性 | 難治性高悪性度B細胞リンパ腫 | 原発性縦隔大細胞型B細胞リンパ腫-難治性 | 緩徐進行性B細胞非ホジキンリンパ腫から難治性びまん性大細胞型B細胞リンパ腫への変化アメリカ
-
Athenex, Inc.募集B細胞リンパ腫 | CLL/SLL | すべて、子供時代 | DLBCL - びまん性大細胞型 B 細胞性リンパ腫 | B細胞白血病 | NHL、再発、成人 | ALL、成体 B 細胞アメリカ
-
Northwestern UniversityNational Cancer Institute (NCI)積極的、募集していないびまん性大細胞型B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫、特に特定されていない | 特に明記されていない高悪性度B細胞リンパ腫 | T細胞/組織球が豊富な大細胞型B細胞リンパ腫 | MYCおよびBCL2および/またはBCL6再構成を伴う高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫活性化B細胞型 | びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型アメリカ
-
Patrick C. Johnson, MDAstraZeneca募集難治性B細胞非ホジキンリンパ腫 | びまん性大細胞型B細胞リンパ腫(DLBCL) | グレード3bの濾胞性リンパ腫 | 難治性攻撃性B細胞リンパ腫 | 攻撃的な B 細胞 NHL | De Novoまたは形質転換された無痛性B細胞リンパ腫 | DLBCL、Nos 遺伝子サブタイプ | T細胞/組織球が豊富な大細胞型B細胞リンパ腫 | EBV陽性のDLBCL、番号 | 原発性縦隔 [胸腺] 大細胞型 B 細胞性リンパ腫 (PMBCL) | 高悪性度 B 細胞性リンパ腫、Nos | C-MYC/BCL6 ダブルヒットの高悪性度 B 細胞性リンパ腫 | C-MYC/BCL2 ダブルヒットの高悪性度 B 細胞性リンパ腫アメリカ
-
Ohio State University Comprehensive Cancer Center募集びまん性大細胞型B細胞リンパ腫 | 高悪性度B細胞リンパ腫 | びまん性大細胞型B細胞リンパ腫、特に特定されていない | びまん性大細胞型 B 細胞リンパ腫 胚中心 B 細胞型アメリカ
-
National Cancer Institute (NCI)積極的、募集していない再発性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型 | 難治性びまん性大細胞型 B 細胞性リンパ腫活性化 B 細胞型アメリカ, サウジアラビア